Financial Disclosure: Dr Glassock has been a consultant and/or an advisor for Vifor Pharmaceuticals (Aspreva) (chairman, Data Monitoring and Safety Committee; ALMS); FibroGen (chairman, Data Monitoring and Safety Board, CTGF Study); Novartis (chairman, Renal and Hypocalcemia Event Adjudication Committee, Zoledronic Acid Studies); Genentech (chair, Data Monitoring and Safety Board, Rituximab in Lupus Nephritis [LUNAR and EXPLORER] Studies; member, Data Safety and Monitoring Board for the Ocreluzimab studies in Lupus Neprhitis and Rheumatoid Arthritis [BELONG, SCRIPT, STAGE, FEATURE, FILM]); Quest Diagnostics/Nichols Institute; Science Partners (also a partner); QuestCor; Gilead Sciences; Wyeth; Bio-Marin; Bristol-Myers Squibb (member of Adjudication Committee for Abatacept in Lupus Nephritis); Eli Lilly (chair, Data Safety and Monitoring Board; and Lighthouse Learning. He has ownership interests in La Jolla Pharmaceuticals Inc (stockholder) and Reata Inc (limited partnership). He has received honoraria from the American Society of Nephrology for lectures and participation in Renal Week Review and Board Review Course and from various medical schools (Harvard University, University of California at San Francisco, University of Florida, the University of Southern California, Cedars Sinai Medical Center, Lupus Foundation of America, Columbia University, and Cornell University) for lectures and/or visiting professorships. He has been employed (part-time, contractual, or multiyear) by the American Society of Nephrology (member, NephSAP editorial board and associate editor and editor emeritus) and UpToDate (editor, Nephrology [Glomerular Diseases] section). Dr Glassock has also received payment from various legal firms for expert testimony regarding product liability. He receives royalties from Lippincott Williams and Wilkins and Oxford University Press. He has been on the board of directors or advisory boards for University Kidney Research Organization (UKRO), Los Angeles Biomedical Institute, Aspreva (Vifor), and Wyeth.